Transformative Bispecific Nanobody Targeting CTLA4 and PDCD1 for Innovative Colon Cancer Immunotherapy
VHH-P332 is a bispecific, humanized nanobody designed to target both cytotoxic T-lymphocyte associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1). Developed using advanced antibody engineering, VHH-P332 is currently in the Biological Testing stage with the potential to address critical immunological checkpoints in the treatment of colon cancer. By selectively engaging CTLA4 and PDCD1, VHH-P332 aims to restore and enhance immune responses against tumor cells, positioning itself as a promising new candidate for immunotherapy in this challenging indication.
| Candidate | VHH-P332 |
| Target | cytotoxic T-lymphocyte associated protein 4 (CTLA4) programmed cell death 1 (PDCD1) |
| Modality | humanized bispecific VHH |
| Indication | Colon Cancer |
Licensing Opportunity
VHH-P332 is currently available for out-licensing and collaborative development opportunities. Partners and investors seeking innovative bispecific nanobody programs for colon cancer immunotherapy are welcome to engage in discussions for further co-development and commercialization.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P332 |
Modality
VHH-P332 utilizes a bispecific nanobody framework composed of two humanized single-domain antibodies, each with specificity for either CTLA4 or PDCD1, connected via a flexible (G4S)2G4 linker and fused to an IgG4 Fc domain. Expressed in human embryonic kidney cells, this modular structure combines the high tissue penetration, small molecular size, and stability of nanobodies with the effector functions and extended half-life provided by the IgG4 Fc. This unique design enhances the ability to reach and modulate the tumor microenvironment in colon cancer, offering improved pharmacokinetic profiles and potential for superior tumor targeting compared to larger conventional antibodies.
Target
CTLA4 and PDCD1 are both immune checkpoint proteins with pivotal roles in regulating T-cell activity. CTLA4 is predominantly expressed on activated T cells and regulatory T cells, while PDCD1 is mainly expressed on T cells upon activation in peripheral tissues. Both CTLA4 and PDCD1 function to downregulate immune responses, helping maintain self-tolerance and preventing autoimmunity. However, in colon cancer, elevated CTLA4 and PDCD1 signaling in the tumor microenvironment suppresses effective anti-tumor immunity. Therapeutic targeting of CTLA4 and PDCD1 has become a well-validated strategy to reactivate immune responses against cancer cells. Targeting both CTLA4 and PDCD1 concurrently with VHH-P332 has strategic significance, as dual inhibition may overcome resistance mechanisms and provide more robust antitumor effects, positioning this approach at the forefront of immuno-oncology innovation for colon cancer.
Mechanism of Action
VHH-P332 exerts its therapeutic effects by binding and simultaneously inhibiting CTLA4 and PDCD1, two essential immune checkpoint molecules that regulate T-cell activation and tolerance. By blocking the inhibitory signals mediated through CTLA4 and PDCD1, VHH-P332 relieves immunosuppression within the tumor microenvironment, thereby promoting the activation and proliferation of cytotoxic lymphocytes to target and destroy colon cancer cells. As a nanobody-based platform, VHH-P332 also offers versatility for future engineering possibilities, such as generating antibody-drug conjugates (ADCs) or multivalent formats for tailored immune modulation. Its bispecific nature expands the spectrum of immunotherapeutic intervention, aiming for synergistic effects and improved clinical outcomes in colon cancer.
Colon Cancer
Colon cancer is one of the leading causes of cancer-related morbidity and mortality worldwide, with a significant global disease burden. Standard treatments include surgical resection, chemotherapy, radiation therapy, immuno-oncology agents, and targeted therapies. Despite advances in screening and therapy, many patients experience limited efficacy with existing modalities, particularly in advanced or metastatic disease, due to tumor heterogeneity, immune evasion, and acquired resistance. Immunotherapies targeting key checkpoint regulators such as CTLA4 and PDCD1 have demonstrated clinical potential, yet combination and bispecific approaches are needed to maximize therapeutic benefit. VHH-P332, by concurrently targeting both CTLA4 and PDCD1, is positioned to address the unmet need for more effective, durable, and targeted immunotherapeutic strategies in the management of colon cancer.